Iryna Kovalenko

Iuliia Kovalenko 2 collaborations

Barbara S Nelson 1 collaboration

Lin Lin 1 collaboration

Daniel M Kremer 1 collaboration

Cristovão M Sousa 1 collaboration

Cecilia Cotta-Ramusino 1 collaboration

Amy Myers 1 collaboration

Johanna Ramos 1 collaboration

Tina Gao 1 collaboration

Ilya Kovalenko 1 collaboration

Kari Wilder-Romans 1 collaboration

Joseph Dresser 1 collaboration

Mary Davis 1 collaboration

Ho-Joon Lee 1 collaboration

Zeribe C Nwosu 1 collaboration

Scott Campit 1 collaboration

Oksana Mashadova 1 collaboration

Brandon N Nicolay 1 collaboration

Zachary P Tolstyka 1 collaboration

Christopher J Halbrook 1 collaboration

Sriram Chandrasekaran 1 collaboration

John M Asara 1 collaboration

Howard C Crawford 1 collaboration

Lewis C Cantley 1 collaboration

Alec C Kimmelman 1 collaboration

Daniel R Wahl 1 collaboration

Costas A Lyssiotis 1 collaboration

V E Orfaly 1 collaboration

I Kovalenko 1 collaboration

S N Tolkachjov 1 collaboration

A G Ortega-Loayza 1 collaboration

J R Nunley 1 collaboration

Wern Lynn Ng 1 collaboration

Yimin Geng 1 collaboration

Yinghong Wang 1 collaboration

Pavlos Msaouel 1 collaboration

Shailender Bhatia 1 collaboration

Petros Grivas 1 collaboration

Raed Benkhadra 1 collaboration

Omar Alhalabi 1 collaboration

Tabinda Saleem 1 collaboration

Mitali Shah 1 collaboration

Sara Seyedroudbari 1 collaboration

Konstantin Golubykh 1 collaboration

Rimsha Ali 1 collaboration

Taaha Mirza 1 collaboration

Babray Laek 1 collaboration

Ahsan Wahab 1 collaboration

Asmi Chattaraj 1 collaboration

Ekaterina Proskuriakova 1 collaboration

Chandi Garg 1 collaboration

Rafiullah Khan 1 collaboration

Publications (4)

Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy.

Tofacitinib for the treatment of refractory pyoderma gangrenosum.

Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients.

Novel Pharmacological Treatment Options of Steroid-Refractory Graft-versus-Host Disease.

Réseau de co-auteurs